Objective: To evaluate the efficacy and safety of lacosamide when added to a single
antiepileptic drug (AED) in patients with partial-onset seizures (POS). Background …

Objective To gather real‐world evidence on antiseizure medications (ASMs) treatment
patterns and related outcomes in patients with drug‐resistant focal epilepsy. Methods …

Purpose Perampanel (PER) and lacosamide (LCM) are antiepileptic drugs (AEDs) approved
for the adjunctive treatment of partial-onset seizures. At the time of market entry, information …

Background This retrospective, observational study used US claims data to assess changes
in antiseizure medication (ASM) drug load for a cohort of patients with epilepsy. Methods …

Objectives To evaluate the effects of nonadherence to antiseizure medications (ASMs) and
clinical characteristics on seizure control, we employed a prospective cohort cross-sectional …

Purpose: To examine the safety and tolerability of rapidly initiating adjunctive lacosamide via
a single intravenous loading dose followed by twice‐daily oral lacosamide in lacosamide …

Objective The objective of this study was to evaluate all-cause and epilepsy-specific
healthcare resource utilization and costs following lacosamide (LCM) initiation as adjunctive …

Objective The goal of this study was to analyze the persistence with antiepileptic drugs
(AED) and associated factors in patients followed in neurological practices in Germany …

Long-term (up to 8 years of exposure) safety and efficacy of the antiepileptic drug
lacosamide was evaluated in this open-label extension trial (SP615 [ClinicalTrials. gov …

Purpose Perampanel (PER) and lacosamide (LCM) are the new third-generation anti-
seizure medications (ASMs) that were approved for the monotherapy of focal epilepsy in …